The 2022 International Census Classification (ICC) system emphasized both blast percentage and genomic factors when discussing the diagnosis of AEL/PEL and classifies this disorder within the broad category of myeloid neoplasms with mutated TP53 due to their similarly aggressive clinical behavior [6]. Here, TP53 is linked to intrahepatic cholangiocarcinoma.